News

Public · Published

B of A Securities maintains Regeneron Pharmaceuticals at Buy, raises price target to $1030 from $908

B of A Securities kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1030 from $908. The new target is a 13.4% increase and implies 11.0% upside from the October 30 closing price of $927.89.

Published:

Updated:

What happened

B of A Securities kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1030 from $908. The new target is a 13.4% increase and implies 11.0% upside from the October 30 closing price of $927.89.

Confirmed

Global impact / market context

A higher target signals that B of A Securities sees more potential value in Regeneron shares, but it is an analyst estimate, not a company forecast or guaranteed return. Investors may use it when weighing expected share gains against the possibility that the estimate proves too optimistic.

Analyst inference

Recent analyst targets span $825 to $1050, with ratings ranging from Neutral to Buy and Overweight. That spread shows analysts disagree on Regeneron’s value; the raised target sits within the range, so it does not establish a shared view of the company’s prospects.

Confirmed

What to watch

  1. Compare future analyst targets and ratings with this $1030 target; widening disagreement could make investor expectations less settled, while convergence would indicate a more consistent view. Analyst inference
  2. Check whether Regeneron reports company updates that explain changes in expected revenue or costs; the article provides no business results or operating outlook behind the target increase. Analyst inference
  3. The article states the target implies 11.0% upside from the October 30 close of $927.89; this comparison is based on that closing price. Confirmed

Evidence

  • Original source link unavailable